- Home
- NGVC vs ZYME Comparison
NGVC vs ZYME Comparison
Compare NGVC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGVC
- ZYME
- Stock Information
- Founded
- NGVC 1955
- ZYME 2003
- Country
- NGVC United States
- ZYME United States
- Employees
- NGVC N/A
- ZYME N/A
- Industry
- NGVC Food Chains
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- NGVC Consumer Staples
- ZYME Health Care
- Exchange
- NGVC Nasdaq
- ZYME Nasdaq
- Market Cap
- NGVC 865.7M
- ZYME 761.2M
- IPO Year
- NGVC 2012
- ZYME 2017
- Fundamental
- Price
- NGVC $47.76
- ZYME $11.53
- Analyst Decision
- NGVC
- ZYME Buy
- Analyst Count
- NGVC 0
- ZYME 6
- Target Price
- NGVC N/A
- ZYME $19.50
- AVG Volume (30 Days)
- NGVC 157.9K
- ZYME 833.8K
- Earning Date
- NGVC 05-08-2025
- ZYME 05-08-2025
- Dividend Yield
- NGVC 1.01%
- ZYME N/A
- EPS Growth
- NGVC 33.38
- ZYME N/A
- EPS
- NGVC 1.56
- ZYME N/A
- Revenue
- NGVC $1,270,056,000.00
- ZYME $76,304,000.00
- Revenue This Year
- NGVC $1.32
- ZYME $26.29
- Revenue Next Year
- NGVC N/A
- ZYME $75.78
- P/E Ratio
- NGVC $30.62
- ZYME N/A
- Revenue Growth
- NGVC 9.31
- ZYME 0.38
- 52 Week Low
- NGVC $15.82
- ZYME $7.97
- 52 Week High
- NGVC $50.91
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- NGVC 69.30
- ZYME 49.31
- Support Level
- NGVC $45.81
- ZYME $10.69
- Resistance Level
- NGVC $48.12
- ZYME $11.48
- Average True Range (ATR)
- NGVC 2.90
- ZYME 0.78
- MACD
- NGVC 0.78
- ZYME 0.10
- Stochastic Oscillator
- NGVC 96.99
- ZYME 81.57
About NGVC Natural Grocers by Vitamin Cottage Inc.
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.